Surgical treatment of early tongue squamous cell carcinoma and patient survival

Abstract

Surgical options for treating early tongue squamous cell carcinoma and patient survival were explored. Clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM from June, 2010 to June, 2013 were retrospectively analyzed. According to adopted treatment plan, the patients were divided into 3 groups: 42 patients in surgical therapy alone group, 46 patients in preoperative radiotherapy group, and 40 patients in postoperative radiotherapy group. Statistical analysis was performed on the general data of patients and clinical records, as well as the 5-year survival rate and recurrence rate. The overall 5-year survival rate for all patients was 86.7% (111/128), and the 5-year disease-specific survival rate was 88.8% (111/125). In the individual groups, the 5-year survival rate and the 5-year disease-specific survival rate were 91.3% (84/92) and 91.3% (84/92), respectively, in the surgical therapy alone group 76.9% (10/13) and 83.3% (10/12), respectively, in the preoperative radiotherapy group, and 73.9% (17/23) and 81.0% (17/21), respectively, in the postoperative radiotherapy group. There were no statistically significant differences in 5-year survival rate (χ 2 =5.990, P=0.051) and 5-year disease-specific survival rate (χ 2 =2.223, P=0.329) among the three groups. In total, there were 25 cases of recurrence during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 6 cases of metastasis, and the metastatic rate was 4.7%. There were no statistically significant differences in recurrence rate and metastatic rate among the three groups. Compared with surgical therapy alone, radiotherapy combined with surgical therapy neither improved 5-year survival rate nor reduced recurrence rate. Therefore, surgical therapy alone is suggested to be the preferred option for treating early tongue squamous cell carcinoma.

WEE1 kinase inhibitor MK‐1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status

“…Currently, surgery is considered the mainstay method of treatment of OTSCC (Zhu et al, 2019). Radiotherapy is also an important modality mostly used for patients with early-stage OTSCC as a monotherapy, which in advanced cases is often combined with chemotherapy after surgery.…”

Ailanthone Inhibits Cell Proliferation in Tongue Squamous Cell Carcinoma via PI3K/AKT Pathway

“…In recent years, death rate caused by TSCC has significantly increased, and the incidence of TSCC has shifted to a younger age [ 3 ]. However, the surgical therapy frequently led to maxillofacial deformity, speech disorder, eating difficult, and other functional disorders, with a high rate of relapse and lymphatic metastasis or distant tissue metastasis [ 4 ]. Therefore, it is urgent to explore novel drugs or targets to treat TSCC.…”

Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines

“…Surgery is still considered the mainstay method of treatment for OTSCC (Zhu et al 2019 ). Radiotherapy, in some cases combined with concomitant cisplatin-based chemotherapy, is applied as adjuvant treatment based on the stage of the tumor, histological findings and surgical margins.…”